pre-IPO PHARMA

COMPANY OVERVIEW

Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. The Company’s lead program, solabegron, is a highly potent and selective beta-3 adrenoceptor agonist that is being developed for overactive bladder (OAB). OAB is a condition that affects the quality of life for more than 80 million people worldwide − a number that will continue to grow as the population ages.


LOCATION

  • Wayne, PA, USA

  • THERAPEUTIC AREAS

  • Urology

  • WEBSITE

    http://www.velicept.com


    CAREER WEBSITE


    SOCIAL MEDIA


    INVESTORS

    becker-ventures cam-capital fountain-healthcare-partners longitude-capital


    PRESS RELEASES


    Mar 28, 2019

    Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)


    Mar 28, 2019

    Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)


    Oct 16, 2018

    Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent


    Oct 16, 2018

    Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent


    Mar 19, 2018

    Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB


    For More Press Releases


    Google Analytics Alternative